NewsMV
A $4.5 million Asset Purchase Agreement, filed with the SEC on September 4, puts two disease-intelligence AI products in focus for $ISPC (iSpecimen Inc., Nasdaq).
The deal targets assets from Foldlab AI Ltd., a British Columbia company, and covers a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model.
Stockholder approval is the gate that must open before the transaction can close. Deal mechanics and gated cash The $4.5 million breaks into $2 million in cash and $2.5 million in iSpecimen common stock.
Of the cash, $750,000 is due at closing by wire. The remaining $1.25 million splits into two milestone payments of $625,000 each, payable only on successful delivery, testing, and acceptance of each AI product.
Keep reading